Software and coaching services that use continuous glucose monitor data to help patients and consumers manage weight, blood sugar, and GLP-1 treatment.
Metabolic & physiological foundation-model applications
Google Research’s GlucoFM release gives tools to read continuous glucose monitor data; Peter Attia’s piece highlights growing interest in GLP-1 medication uses beyond weight loss; and Forbes reports fresh FDA drug approval signaling pharma momentum. That mix makes now a sensible moment to offer software and coaching that tie continuous glucose monitor data to weight, blood sugar, and GLP-1 care.
Projected Score
as a side gig ☆☆☆☆☆ (0/5)
no money or audience ★☆☆☆☆ (1/5)
with both ★★★☆☆ (3/5)
Want this one researched? Commission the full dossier for $15: we research and write it, and you read it first. Then you choose — pay more to keep it exclusive, or do nothing and it goes public on this site. The score above is our forecast for a dossier we haven’t written yet.
The news behind it
- Aug 27, 2026 Google Research blog: GlucoFM: Foundation model for continuous glucose monitoring
- Aug 27, 2026 Peter Attia: GLP-1 medications beyond weight loss: how far could their benefits extend?
- Aug 27, 2026 Forbes (contributor net): FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results
